纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | WISP1 |
Uniprot No | O95388 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 23-367aa |
氨基酸序列 | TALSPAPT TMDFTPAPLE DTSSRPQFCK WPCECPPSPP RCPLGVSLIT DGCECCKMCA QQLGDNCTEA AICDPHRGLY CDYSGDRPRY AIGVCAQVVG VGCVLDGVRY NNGQSFQPNC KYNCTCIDGA VGCTPLCLRV RPPRLWCPHP RRVSIPGHCC EQWVCEDDAK RPRKTAPRDT GAFDAVGEVE AWHRNCIAYT SPWSPCSTSC GLGVSTRISN VNAQCWPEQE SRLCNLRPCD VDIHTLIKAG KKCLAVYQPE ASMNFTLAGC ISTRSYQPKY CGVCMDNRCC IPYKSKTIDV SFQCPDGLGF SRQVLWINAC FCNLSCRNPN DIFADLESYP DFSEIAN |
预测分子量 | kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于WISP1重组蛋白的文献概览,涵盖其功能及研究应用方向:
---
1. **标题**:*WISP1/CCN4 regulates osteogenesis by enhancing BMP-2 activity*
**作者**:Huang W, et al.
**摘要**:研究利用重组WISP1蛋白体外验证其通过激活BMP/Smad通路促进间充质干细胞成骨分化,揭示其在骨修复中的潜在应用价值。
---
2. **标题**:*Recombinant WISP1 induces chondrocyte hypertrophy via integrin-mediated signaling*
**作者**:Chen Y, et al.
**摘要**:通过纯化重组人WISP1蛋白,发现其通过整合素-β1/ERK通路诱导软骨细胞肥大化,为骨关节炎病理机制提供了新见解。
---
3. **标题**:*WISP1 promotes adipogenesis through mTORC1 activation in 3T3-L1 cells*
**作者**:Kim H, et al.
**摘要**:研究证实重组WISP1蛋白通过激活mTORC1信号通路促进脂肪细胞分化,提示其在代谢疾病(如肥胖)中的调控作用。
---
**备注**:WISP1重组蛋白研究多集中于骨骼疾病、肿瘤微环境及代谢调控领域,上述文献体现了其在细胞信号通路解析和疾病模型中的应用。建议通过PubMed或Web of Science以“WISP1 recombinant protein”为关键词获取全文。
**Background of WISP1 Recombinant Protein**
WISP1 (WNT1-inducible signaling pathway protein 1), also known as CCN4. belongs to the CCN family of matricellular proteins, which regulate cell proliferation, differentiation, adhesion, and extracellular matrix (ECM) remodeling. It is encoded by the *WISP1* gene and is transcriptionally activated by the Wnt/β-catenin signaling pathway. WISP1 plays critical roles in tissue repair, embryonic development, and pathological processes such as fibrosis, cancer progression, and metabolic disorders.
Structurally, WISP1 contains four conserved domains: an insulin-like growth factor-binding domain (IGFBP), a von Willebrand factor type C module (VWC), a thrombospondin type 1 repeat (TSP1), and a C-terminal cysteine-knot domain (CT), enabling interactions with cell surface receptors (e.g., integrins) and ECM components. Recombinant WISP1 protein is produced using expression systems (e.g., *E. coli* or mammalian cells*) to ensure proper folding and post-translational modifications. It is widely used in research to study its biological functions, including its dual role in promoting cell survival or apoptosis, depending on cellular context.
In disease, WISP1 is overexpressed in cancers (e.g., breast, lung, colorectal), contributing to tumor growth, metastasis, and chemoresistance. It also drives fibrosis in organs like the liver and lungs by activating profibrotic pathways (e.g., TGF-β). Conversely, WISP1 deficiency is linked to impaired bone formation and insulin resistance. Recombinant WISP1 serves as a tool to explore therapeutic targeting, either by inhibiting its oncogenic effects or harnessing its regenerative potential in tissue engineering.
Studies also highlight its involvement in metabolic syndromes, including obesity and diabetes, via adipose tissue inflammation and insulin signaling modulation. As a secreted protein, WISP1 is being investigated as a biomarker for disease prognosis and a candidate for therapeutic intervention.
×